A Prospective study of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE and Concurrent Capecitabine in Metastatic Paragangliomas

被引：0
|
作者：
Ballal, S. [1 ]
Yadav, M. P. [1 ]
Yadav, D. [1 ]
Bal, C. [1 ]
机构：
[1] All India Inst Med Sci, New Delhi, India
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-169
引用
收藏
页码：S184 / S184
页数：1
相关论文
共 50 条
  • [1] Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE
    Zandee, Wouter T.
    Feelders, Richard A.
    Duijzentkunstz, Daan A. Smit
    Hofland, Johannes
    Metselaar, R. Mick
    Oldenburg, Rogier A.
    van Linge, Anne
    Kam, Boen L. R.
    Teunissen, Jaap J. M.
    Korpershoek, Esther
    Hendriks, Johanna M.
    Abusaris, Huda
    Slagter, Cleo
    Franssen, Gaston J. H.
    Brabander, Tessa
    De Herder, Wouter W.
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (01) : 45 - 53
  • [2] Dramatic response with peptide receptor radionuclide therapy with 177Lu-DOTATATE and capecitabine in the treatment of metastatic thymic carcinoma
    Bal, C.
    Ballal, S.
    Tripati, M.
    Chakraborty, P.
    Thakral, P.
    Arora, G.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [3] Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
    Madhav Prasad Yadav
    Sanjana Ballal
    Chandrasekhar Bal
    [J]. EJNMMI Research, 9
  • [4] Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrasekhar
    [J]. EJNMMI RESEARCH, 2019, 9 (1)
  • [5] Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma
    Deville, Agathe
    Pinigina, Iuliia
    Al Mansour, Laure
    Abeillon, Juliette
    Tordo, Jeremie
    [J]. CLINICAL NUCLEAR MEDICINE, 2022, 47 (01) : E71 - E73
  • [6] In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy
    Lubberink, Mark
    Wilking, Helena
    Ost, Amalia
    Ilan, Ezgi
    Sandstrom, Mattias
    Andersson, Camilla
    Fross-Baron, Katarzyna
    Velikyan, Irina
    Sundin, Anders
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (09): : 1337 - 1340
  • [7] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings
    Mok, S.
    Tay, Y.
    Ng, D.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [8] Receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumours
    Bodei, L.
    Cremonesi, M.
    Grana, C.
    Bartolomei, M.
    Baio, S.
    Bufi, G.
    Fiorenza, M.
    Obenaus, E.
    Paganelli, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S214 - S214
  • [9] Biphasic exponential dosimetry model for 177Lu-DOTATATE peptide receptor radionuclide therapy
    Chen, Sirong
    Cheng, Kam
    Li, Ka Chun
    Leung, Yim Lung
    Cheung, William
    Wong, Ka Nin
    Wong, Yuet Hung
    Ho, Chi-Lai
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [10] In-vivo stability of 177Lu-DOTATATE during peptide receptor radionuclide therapy
    Wilking, H.
    Ilan, E.
    Sandstrom, M.
    Andersson, C.
    Ost, A.
    Velikyan, I.
    Fross-Baron, K.
    Sundin, A.
    Lubberink, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S592 - S592
12345